Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection—the InC3Study

Abstract
Background. We aimed to characterize the natural history of hepatitis C virus (HCV) reinfection and spontaneous clearance following reinfection (reclearance), including predictors of HCV reclearance. Methods. Data were synthesized from the 9 prospective cohorts of the International Collaboration of Incident Human Immunodeficiency Virus and HCV in Injecting Cohorts study, which evaluated HCV infection outcomes among people who inject drugs. Participants with primary HCV infection were classified as having achieved viral suppression if they had negative results of at least 1 subsequent HCV RNA test. Those with positive results of an HCV RNA test following viral suppression were investigated for reinfection. Viral sequence analysis was used to identify reinfection (defined as detection of heterologous virus with no subsequent detection of the original viral strain). Results. Among 591 participants with acute primary HCV infection, 118 were investigated for reinfection. Twenty-eight participants were reinfected (12.3 cases/100 person-years; 95% confidence interval [CI], 8.5–17.8). Peak HCV RNA level was lower during reinfection than primary infection (P = .011). The proportion of individuals with reclearance 6 months after reinfection was 52% (95% CI, 33%–73%). After adjustment for study site, females with the IFNL4 (formerly IFNL3 and IL28B) rs12979860 CC genotype detected were more likely to have reclearance (hazard ratio, 4.16; 95% CI, 1.24–13.94; P = .021). Conclusions. Sex and IFNL4 genotype are associated with spontaneous clearance after reinfection.
Funding Information
  • National Institute on Drug Abuse
  • National Institutes of Health
  • National Institutes of Health
  • NIH (U19 AI088791, U19 AI066345)
  • National Institute on Drug Abuse
  • NIH (R01 DA031056, R01 DA033541, R01 DA016017, R01 DA15999-01)
  • the Victorian Operational Infrastructure Support Program
  • National Health and Medical Research Council
  • (postgraduate scholarship
  • practitioner research fellowships to
  • Senior Research Fellowships
  • career development fellowship to (630483, 331312)
  • Fonds de la Recherche du Québec–Santé (research career awards
  • an Australian postgraduate PhD award
  • Canadian Institutes of Health Research (MOP-103138, MOP-106468)
  • the Netherlands National Institute for Public Health and the Environment
  • the University of New South Wales Hepatitis C Vaccine Initiative
  • The Australian Centre for HIV and Hepatitis Virology Research
  • Centre for Research Excellence into Injecting Drug Use